Psoriasis assessment tools in clinical trials

Feldman, Steven R.; Krueger, Gerald G.

doi:10.1136/ard.2004.031237

Cited by 415 publications

(405 citation statements)

References 22 publications

Supporting

Mentioning

386

Contrasting

Unclassified

Order By: Relevance

“…This measure is often employed in clinical trials of therapies for psoriasis and PsA, but it is not routinely used in clinical practice 17 . Criticisms of the PASI include decreased interrater agreement for high scores and poor sensitivity for treatment that decreases erythema, scaling, and infiltration of lesions when there is no modification of BSA affected 21 .…”

Section: Discussionmentioning

confidence: 99%

“…While it has been used extensively in clinical trials, the PASI is not sensitive to change for small areas of involvement, and it is not often employed in clinical practice 17 . The physician global assessment of disease activity (PGA) is another measure for psoriasis that has been used extensively in clinical trials and it may be employed in a static form that measures the physician's impression of the disease at a point in time or in a dynamic form in which the global improvement from baseline is evaluated 17 . The PGA is highly correlated with the PASI, and results from 1 study showed that the correlation between PASI75 and a score of PGA "Clear" or "Almost clear" is r 2 > 0.9 18,19 .…”

Section: Rheumatologymentioning

confidence: 99%

See 1 more Smart Citation

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

et al. 2013

View full text Add to dashboard Cite

Objective.This posthoc analysis evaluated the percentage of patients with psoriatic arthritis (PsA) who achieved minimal disease activity (MDA) and compared the results with a modified MDA substituting the physician global assessment (PGA) for the Psoriasis Activity and Severity Index (PASI) using data from the ADalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT; NCT00646386).Methods.Patients with active PsA were randomized to receive adalimumab 40 mg or placebo every other week for 24 weeks. MDA was defined as achieving ≥ 5 of the following criteria: tender joint count ≤ 1; swollen joint count ≤ 1; PASI ≤ 1 or body surface area ≤ 3%; patient pain score ≤ 15 [1–100 mm visual analog scale (VAS)]; patient global assessment (PGA) of disease activity ≤ 20 (1–100 mm VAS); Health Assessment Questionnaire ≤ 0.5; and tender entheseal points ≤ 1 (only heels assessed). For modification of the MDA, PASI ≤ 1 was substituted with PGA “Clear” as MDAPGA1 and PGA “Clear” or “Almost clear” as MDAPGA2.Results.Sixty-seven patients were treated with adalimumab and 69 with placebo. At Week 24, MDA, MDAPGA1, and MDAPGA2 were achieved by 39%, 37%, and 39%, respectively, of patients treated with adalimumab versus 7%, 5%, and 8% of patients on placebo (p < 0.001). Kappa coefficients indicated good agreement between PASI and PGA at Week 24.Conclusion.ADEPT results indicated that significantly more patients treated with adalimumab achieved MDA by Week 24 compared with placebo. Modification of the MDA by replacing PASI ≤ 1 with PGA assessments did not alter the results, which may improve feasibility of practical use of the index.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Rheumatologymentioning

confidence: 99%

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Comprehensive assessment of patients with psoriatic arthritis (PsA) involves evaluation of joints, dactylitis, skin, and nails (1)(2)(3)(4)(5). Nail lesions are very common and help distinguish between patients who have PsA and those who have rheumatoid arthritis (6).…”

Section: Introductionmentioning

confidence: 99%

Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?

Lubrano

Cantini

Marchesoni

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…PASI assessment gets more reliable by experience. 21 Definition for 'clinically meaningful success' is still problematic in psoriasis. The current consensus for clinically meaningful improvement in psoriatic patients is at least 50-75% improvement in disease, which has been translated into 50-75% improvement in the PASI score.…”

Section: Discussion Summary Of Main Resultsmentioning

confidence: 99%

Effect of omega‐3 fatty acids on disease severity in patients with psoriasis: A systematic review

et al. 2017

View full text Add to dashboard Cite

Aim: Many randomized controlled trials have been performed on the efficacy and mechanism of action of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on psoriasis. However, contradictory results have been obtained. This study wants to assess the effects of n-3 PUFAs on the severity of psoriasis. Methods:The Cochrane Central Register of Controlled Trials, PubMed/MEDLINE and EMBASE were searched for all randomized controlled trials and prospective observational studies comparing the efficacy of n-3 PUFAs versus control in adult patients with psoriasis. The primary outcome was psoriasis severity as measured by the Psoriasis Area Severity Index (PASI) score. Results:The initial search yielded 732 articles, 720 of which were excluded. The data of the 12 remaining studies were extracted. Some studies found that n-3 PUFAs were associated with improvements in the PASI score, erythema, scaling, itching, area involved and infiltration. However, some studies did not find reduction in scaling, erythema, area involved or thickness in the treatment group. Conclusion:It is still inconclusive whether use of n-3 PUFAs in patients with psoriasis is associated with improvements in severity of psoriasis and other outcomes.

show abstract

Psoriasis assessment tools in clinical trials

Cited by 415 publications

References 22 publications

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?

Effect of omega‐3 fatty acids on disease severity in patients with psoriasis: A systematic review

Contact Info

Product

Resources

About